Search
- Dec 27, 2023
Xontogeny's Chris Garabedian gives a year-end review and looks ahead to biotech's 2024
Chris Garabedian's thoughts on the IPO market, products vs platforms, and more discipline and prioritization in biotech.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A